Christopher Reardon
About Christopher Reardon
Christopher Reardon is the Lead Process Design Engineer for AAV Production at Dyno Therapeutics in Watertown, Massachusetts. He has a strong background in biochemistry and molecular biology, with extensive experience in gene therapy and AAV production.
Company
Christopher Reardon is currently employed at Dyno Therapeutics, a biotechnology company located in Watertown, Massachusetts. Dyno Therapeutics is known for its work in gene therapy and AAV vector production. Reardon holds the position of Lead Process Design Engineer, specializing in AAV production processes.
Title
Christopher Reardon serves as the Lead Process Design Engineer, AAV Production, at Dyno Therapeutics. In this role, he focuses on developing and optimizing processes for the production of adeno-associated virus (AAV) vectors, which are critical in gene therapy applications.
Education and Expertise
Christopher Reardon holds a Bachelor of Science degree in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst. His educational background provides a solid foundation for his work in gene therapy and AAV production. Reardon has developed expertise in high-throughput processes and is dedicated to continuous learning and professional development in the field.
Professional Background
Christopher Reardon's professional journey began as a Laboratory Teachers Assistant and then as a Hotel Concierge/Greeter at the University of Massachusetts Amherst. He then worked as a Lab Technician and Data Management Advisor at AB Biosciences. Reardon has also held various roles at Dyno Therapeutics, including Associate Scientist, Senior Research Associate, and now Lead Process Design Engineer. Prior to joining Dyno Therapeutics, he worked at Obsidian Therapeutics and the University of Massachusetts Medical School as a Research Associate.
Achievements
Christopher Reardon has developed a novel high-throughput process for AAV production that significantly reduces production time. He actively participates in gene therapy community events and conferences, showcasing his commitment to advancing the field. Reardon has a passion for pushing the boundaries of traditional AAV production methods and continuously pursues professional development to stay at the forefront of gene therapy innovations.